Comparison of Anti-Inflammatory Property of Coenzyme Q10 with Diclofenac Sodium - An In Vitro Study

Abstract

Introduction: Postoperative inflammation and pain present significant clinical challenges in minor oral surgical procedures, often impeding healing and compromising the patient comfort. While systemic non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac sodium are commonly prescribed for anti-inflammatory and analgesic effects, their use is frequently associated with notable gastrointestinal and other systemic side effects. This has led to a growing interest in localized drug delivery systems, which can target the inflammation directly at the surgical site, thereby maximizing therapeutic efficacy while minimizing systemic exposure. Coenzyme Q10 (CoQ10), a naturally occurring antioxidant, has shown promising anti-inflammatory and wound-healing properties. Therefore, this in vitro study aimed to develop and evaluate a novel CoQ10-based local delivery system and compare its anti-inflammatory activity against the conventional NSAID, diclofenac sodium.

Materials & Methods: In this study, test solutions of diclofenac sodium and CoQ10-loaded film extract were prepared for in vitro evaluation. Diclofenac sodium was first dissolved in dimethyl sulfoxide (DMSO) and then diluted with phosphate-buffered saline (PBS) to obtain concentrations ranging from 10 to 500 μg/mL. For CoQ10, a pre-weighed portion of the film was incubated in PBS at 37°C for 24 hours to allow release, after which the solution was filtered and diluted to achieve equivalent concentrations. The anti-inflammatory activity was assessed using the albumin denaturation assay, where egg albumin solution was mixed with the test samples and subjected to heat-induced denaturation at 70°C for 20 minutes, with PBS and albumin alone serving as the control. Absorbance was measured at 660 nm, and the percentage inhibition of protein denaturation was calculated. Both diclofenac sodium and CoQ10 showed a concentration-dependent increase in activity, with diclofenac sodium proving more effective (57–80% inhibition) but CoQ10 also showing promising results (43–65% inhibition), supporting its potential as a useful anti-inflammatory agent in surgical applications.

Results: The findings of this study demonstrated that the CoQ10-based formulation exhibited substantial anti-inflammatory efficacy. The degree of protein denaturation inhibition was comparable to that observed with diclofenac sodium at similar concentrations. This indicates that CoQ10 possesses potent anti-inflammatory capabilities that could be harnessed for targeted therapeutic application. Its ability to effectively inhibit protein denaturation highlights its promising role in managing postoperative inflammation without the systemic side effects associated with oral NSAIDs.

Conclusion: The present study successfully validates that Coenzyme Q10, when formulated as a localized delivery system, is a promising and biocompatible alternative for managing postoperative inflammation. These in vitro results suggest that CoQ10 could serve as a valuable therapeutic adjunct, aligning with the increasing demand for evidence-based and patient-centric care. The findings not only expand the therapeutic landscape of oral surgery but also provide a strong rationale for future clinical trials to further explore CoQ10's broader regenerative and analgesic properties. Ultimately, integrating such novel biomolecules into routine clinical practice may redefine perioperative management standards, improve patient outcomes while reduce reliance on synthetic pharmaceuticals.